Financhill
Back

NewAmsterdam Pharma Co NV Quote, Financials, Valuation and Earnings

Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!

Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)
Buy
82

NAMS
NewAmsterdam Pharma Co NV

Last Price:
25.55
Seasonality Move:
50.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Better Than Oil Stocks

CLICK HERE TO FIND OUT MORE

NewAmsterdam Pharma Co NV Price Quote

$25.55
-0.64 (-2.44%)
(Updated: December 11, 2024 at 5:55 PM ET)

NewAmsterdam Pharma Co NV Key Stats

Buy
82
NewAmsterdam Pharma Co NV (NAMS) is a Buy

Day range:
$22.23 - $26.36
52-week range:
$9.61 - $26.36
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
70.23
P/B ratio:
6.39%

Volume:
9.3M
Avg. volume:
961.3K
1-year change:
167.24%
Market cap:
$2.4B
Revenue:
$14.1M
EPS:
$-2.25

How Much Does NewAmsterdam Pharma Co NV Make?

Is NewAmsterdam Pharma Co NV Growing As A Company?

NewAmsterdam Pharma Co NV Stock Price Performance

What Is NewAmsterdam Pharma Co NV 52-Week High & Low?

NewAmsterdam Pharma Co NV Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy NewAmsterdam Pharma Co NV?

Is NewAmsterdam Pharma Co NV Cash Flow Positive?

  • What Is NAMS Cash Flow From Operations?
    Cash flow from operations (TTM) is -$154.2M
  • What Is NewAmsterdam Pharma Co NV’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $202.9M
  • What Is NewAmsterdam Pharma Co NV’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$672K

NewAmsterdam Pharma Co NV Return On Invested Capital

  • Is Management Doing A Good Job?
    NAMS return on invested capital is -54.26%
  • What Is NewAmsterdam Pharma Co NV Return On Assets?
    ROA measures how assets are converting to revenues and is -46.22%
  • What Is NAMS Return On Equity?
    ROE is a measure of profitability and is -51.66%

NewAmsterdam Pharma Co NV Earnings Date & Stock Price

NewAmsterdam Pharma Co NV Competitors

NewAmsterdam Pharma Co NV Dividend Yield

NewAmsterdam Pharma Co NV Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 63.08%
Revenue: 889.83% 1508.13%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 40.11
Upside from Last Price: 53.13%

Major Shareholders

  • How many NAMS shares are owned by institutional investors?
    88.8M NAMS shares are owned by institutional investors
  • How many NAMS shares are owned by insiders?
    230.8K NAMS shares are owned by insiders